Neutrophil to lymphocyte ratio varies in magnitude and biomarker utility based on patient demographics
Ang et al. show that a widely studied biomarker for immunotherapy varies based on patient demographics, and that it may only predict outcomes in certain populations.
Authors
- Travis Kerr (ORCID: https://orcid.org/0000-0001-5460-860X)
- Joris L. Vos (ORCID: https://orcid.org/0000-0002-8318-5455)
- Wei-Wen Ang (ORCID: https://orcid.org/0000-0003-4465-0489)
- Daniel J. McGrail (ORCID: https://orcid.org/0000-0002-6669-6069)
- Natalie L. Silver (ORCID: https://orcid.org/0000-0003-4618-6659)
- Sujata Patil (ORCID: https://orcid.org/0000-0003-1706-5321)
- Stephanie L. Schmit (ORCID: https://orcid.org/0000-0001-5931-1194)
- Cristina Valero (ORCID: https://orcid.org/0000-0003-3397-2888)
- Luc G.T. Morris (ORCID: https://orcid.org/0000-0002-4417-2280)
- Vladimir Makarov
- Alex A. Adjei (ORCID: https://orcid.org/0000-0002-8039-6556)
- Ananya Kodiboyena
Institutions
- Cleveland Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cancer Institute (WIA) (IN)
- Cleveland Clinic Lerner College of Medicine (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Journal of Clinical Investigation
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1172/jci198948
- Citations
- 2
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Institutes of Health
- National Cancer Institute